Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble ur...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Loosen, Sven H., Gorgulho, Joao, Jördens, Markus S., Schulze-Hagen, Maximilian, Beier, Fabian, Vucur, Mihael, Schneider, Anne T., Koppe, Christiane, Mertens, Alexander, Kather, Jakob N., Tacke, Frank, Keitel, Verena, Brümmendorf, Tim H., Roderburg, Christoph, Luedde, Tom
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047604/
https://ncbi.nlm.nih.gov/pubmed/33869041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.646883
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares